Landiolol
Reconstitution onlyFull monograph review pending
U.S. label preparation
Rapiblyk · Reconstitution only
- Preparation
- Reconstitute the 280 mg vial with 50 mL of 0.9% sodium chloride or 5% dextrose (5.6 mg/mL).
- Administration and handling
- The room-temperature use period differs by fluid. Follow Table 2 and the prescribed titration.
| Fluid used for reconstitution | Labeled use period |
|---|---|
| 50 mL of 0.9% sodium chloride | Within 4 hours |
| 50 mL of 5% dextrose | Within 48 hours |
Use immediately when possible. Table 2 provides the manufacturer's handling limits. A compounding beyond-use date requires a separate assessment.
Product and source details
AOP Health US, LLC · NDA217202
Product NDC: 87073-110
SPL effective 2026-02-13 | SPL version 6. Checked 2026-11-13.
Source for this summary: U.S. prescribing information. Use the full label for dose selection, contraindications, preparation tables and monitoring.
Product identifiers and clinical review status
U.S. label preparation available. Full monograph review pending.
Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.
What remains to be completed
- Obtain independent corroboration of the label preparation where available.
- Complete indication- and age-specific dosing, incompatibility, monitoring and stability review.
- Assess any proposed compounding BUD for the exact formulation, concentration, container and conditions.